Pichardo-Bahena R, Paz-Gómez FJ, Ávalos RD, Barredo PBA, Ruiz GNI, Méndez-Sánchez N

Language: Spanish
References: 15
Page: 222-226
PDF size: 107.61 Kb.

ABSTRACT

Backgraund: In esophageal adenocarcinoma originated in Barrett's esophagus (BE), has been identify the overexpression of K1-67 and p53, the overexpression haven’t been evaluated extensible in subjects with BE with out dysplasia. Objective: To compare and quantification the expression of Ki-67 and p53 in subject with BE and gastric metaplasia (GM) a case series. Methods: Were selected subjects with gastroesophageal reflux disease and biopsy of the esophagus, with diagnosis of BE o GM and with the slide and paraffin-embedded tissue. It was made immunohistochemestry in each one of theme with antibodies anti Ki-67 and p53. We counted 100 nucleuses for each case of plane squamous epithelium and in the glandular epithelium obtain the average of positive nucleus per each case. Results: Six cases with the diagnostic of BE and four with GM. A case of BE was identify low grade dysplasia. We not found differences between the average of expression in both type of epithelium, and the ranges of expression were variables. Conclusion: There is a sobrexpression of Ki-67 and p53 in both epithelium. Probably the persistent stimuli in these epithelium and the expression of a tumors gene suppressor and cellular proliferation factor may be the mechanism of trigger the stimuli for the development of metaplastic tissue.

REFERENCES

1. Sharma P. Barrett esophagus: will effective treatment prevent the risk of progression to esophageal adenocarcinoma? Am J Med 2004 Sep 6;117 Suppl 5A: 79S-85S.

2. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, Shaheen NJ, Sonnenberg A, Wang K, Weinstein W; AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-330.

3. Csendes A. Surgical treatment of Barrett’s esophagus: 1980-2003. World J Surg 2004; 28: 225-231.

4. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett’s oesophagus. Gut 1991; 32: 1441-1446.

5. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 1988; 19: 166-178.

6. Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164: 1482-1488.

7. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 15: 2049-2053.

8. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2001/, 2004.

9. Beilstein M, Silberg D. Cellular and molecular mechanisms responsible for progression of Barrett’s metaplasia to esophageal carcinoma. Gastroenterol Clin North Am 2002; 31: 461-479, ix.

10. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A. p53 Protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-432.

11. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett’s esophagus. Gastroenterology 1994; 107: 1012-1018.

12. Bani-Hani K, Martin IG, Hardie LF, Mapstone N, Briggs JA, Forman D, Wild CP. Prospective study of cyclin D1 overexpression in Barrett’s esophagus: associating with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92: 1316-1321.

13. Trudgill NJ, Suvarna SK, Royds JA, Riley SA. Cell cycle regulation in patients with intestinal metaplasia at the gastro–oesophageal junction. Mol Pathol 2003; 56: 313–317.

14. Fujii T, Nakagawa S, Hanzawa M, Sueyoshi S, Fujita H, Shirouzu K, Yamana H. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett’s esophagus. Oncol Rep 2003; 10: 427-431.

15. Segal F, Kaspary AP, Prolla JC, Leistner S. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett’s esophagus. Cancer Lett 2004; 210: 213-218.